Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Indian J Ophthalmol ; 65(8): 754-757, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28820168

RESUMEN

PURPOSE: To report the response of cavernous haemangioma of the disc to PDT. METHODS AND PATIENTS: A 32 years old lady presented to us with complaints of sudden onset of blurry vision in her right eye. What seemed initially as polypoidal choroidal vasculopathy turned out as cavernous haemangioma of the disc after pneumatic displacement of the sub-retinal haeme. She was treated with PDT as she was prone to recurrent haemorrhage from the lesion due to her low platelet count. RESULTS: Complete regression of the cavernous haemangioma was noted as early as the second week itself and remained regressed for 4 months. CONCLUSION: PDT can be safe option for patients presenting with symptomatic cavernous haemangioma of the disc or retina.


Asunto(s)
Hemangioma Cavernoso/tratamiento farmacológico , Disco Óptico/patología , Neoplasias del Nervio Óptico/tratamiento farmacológico , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/uso terapéutico , Adulto , Femenino , Angiografía con Fluoresceína , Fondo de Ojo , Hemangioma Cavernoso/diagnóstico , Humanos , Neoplasias del Nervio Óptico/diagnóstico , Agudeza Visual
3.
Indian J Ophthalmol ; 63(12): 888-90, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26862091

RESUMEN

AIM: To study the effect of lanosterol on age-related cataractous human lens nuclei. MATERIALS AND METHODS: Forty age-related cataractous nuclei removed during manual small incision cataract surgery were obtained and randomly immersed in 25 mM lanosterol solution or in control solution and stored at room temperature for 6 days. Pre- and post-immersion photographs were graded by two masked observers and collated for the regression or progression of lens opacity. RESULTS: Both lanosterol and control groups showed progression or no change in the lens opacity at the end of 6 days. CONCLUSION: Lanosterol 25 mM solution did not reverse opacification of human age-related cataractous nuclei.


Asunto(s)
Catarata/tratamiento farmacológico , Lanosterol/farmacología , Núcleo del Cristalino/efectos de los fármacos , Agregación Patológica de Proteínas/tratamiento farmacológico , Catarata/diagnóstico , Extracción de Catarata , Cristalinas/efectos de los fármacos , Progresión de la Enfermedad , Humanos , Implantación de Lentes Intraoculares , Núcleo del Cristalino/patología , Estudios Prospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA